Blog & Resources Camargo Blog April 12th, 2012

NIH Head Urges Repositioning/Repurposing

In a speech at yesterday’s 2012 TEDMED conference, the head of the NIH, Dr. Francis Collins, said that there is a big gap between basic research and drugs for patients. To bridge this gap he suggested ‘some of those old drugs could be re-purposed — or taught new tricks’ – hey, that’s our tag line!

In fact, the NIH has been encouraging this type of research for some time. One example is the establishment of the Pediatric Trials Network (PTN) at the Duke Clinical Research Institute. The NIH grant provides funding for trials that bridge what is known for existing drugs designed for adults to a pediatric population. Madeira Therapeutics is one such company seeking to use the PTN to conduct a trial. A sponsor could develop a formulation and have the clinical trials funded by the PTN.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights